Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process Method Does Not Require Antibody Conjugated Metallic Nanoparticles
Halberd Corporation recently announced a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated to antibodies. This simplified method for the removal of disease-causing antigen(s) utilizes more conventional medical equipment found in hospitals and clinics and utilizes our patented extracorporeal treatment process. The method promises to simplify the commercial stocking and delivery of treatment materials and reduces costs associated with administration of treatments.
William A. Hartman, Halberd’s Chairman, President and CEO, said “This simplified treatment process will be developed simultaneously with the radio frequency and laser emissive energy concepts. Halberd will initially target this process for application to the treatment of Alzheimer’s Disease, which will involve three peptide/protein antigens – tau, phosphorylated tau, and beta amyloid – plus four inflammatory cytokines linked to the development and progression of Alzheimer’s Disease. Details forthcoming as provisional patent applications are being prepared while development work continues. We are extremely excited about this concept since it reduces development time and cost while offering greater acceptability in the market and greater commercial opportunities for Halberd Corporation.”
Halberd Corporation is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies. Halberd also holds the exclusive rights to the underlying granted US Patent 9,216,386 and US Patent 8,758,287.
Total Page Views: 1073